5,625 reports of this reaction
3.7% of all DOCETAXEL ANHYDROUS reports
#5 most reported adverse reaction
HAIR DISORDER is the #5 most commonly reported adverse reaction for DOCETAXEL ANHYDROUS, manufactured by Hospira, Inc.. There are 5,625 FDA adverse event reports linking DOCETAXEL ANHYDROUS to HAIR DISORDER. This represents approximately 3.7% of all 152,096 adverse event reports for this drug.
Patients taking DOCETAXEL ANHYDROUS who experience hair disorder should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAIR DISORDER is moderately reported among DOCETAXEL ANHYDROUS users, representing a notable but not dominant share of adverse events.
In addition to hair disorder, the following adverse reactions have been reported for DOCETAXEL ANHYDROUS:
The following drugs have also been linked to hair disorder in FDA adverse event reports:
HAIR DISORDER has been reported as an adverse event in 5,625 FDA reports for DOCETAXEL ANHYDROUS. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAIR DISORDER accounts for approximately 3.7% of all adverse event reports for DOCETAXEL ANHYDROUS, making it a notable side effect.
If you experience hair disorder while taking DOCETAXEL ANHYDROUS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.